Pharvaris (PHVS)

NASDAQ:PHVS

PHVS

Pharvaris

RESEARCH TOOLSreports

Pharvaris (PHVS) Stock Forecast & Price Target

167 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PHVS Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Pharvaris

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PHVS Stock 12 Month Forecast

Average Price Target

$44.80

▲(62.55% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Pharvaris in the last 3 months. The average price target is $44.80 with a high forecast of $60.00 and a low forecast of $30.00. The average price target represents a 62.55% change from the last price of $27.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","25":"$25","37":"$37","49":"$49","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,25,37,49,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.45,31.8,34.15,36.5,38.85,41.2,43.55,45.9,48.25,50.6,52.95,55.3,57.650000000000006,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.45,30.63076923076923,31.81153846153846,32.99230769230769,34.17307692307692,35.35384615384615,36.534615384615385,37.715384615384615,38.896153846153844,40.07692307692307,41.25769230769231,42.43846153846154,43.61923076923077,{"y":44.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.45,29.49230769230769,29.534615384615385,29.576923076923077,29.619230769230768,29.661538461538463,29.703846153846154,29.746153846153845,29.788461538461537,29.83076923076923,29.873076923076923,29.915384615384614,29.95769230769231,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.43,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$44.80

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andy Chen

Wolfe Research

$42

Buy

52.39%

Upside

Initiated

04/08/26

Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and Pharvaris (NASDAQ: PHVS)

Maxwell Skor

Morgan Stanley

$41

Buy

48.77%

Upside

Reiterated

04/08/26

Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)

Patrick Trucchio

H.C. Wainwright

$60

Buy

117.71%

Upside

Reiterated

04/07/26

Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target

Laura Chico

Wedbush

$41→$42

Buy

52.39%

Upside

Reiterated

04/07/26

Pharvaris price target raised to $42 from $41 at WedbushPharvaris price target raised to $42 from $41 at Wedbush

Nevin Varghese

RBC Capital

Not Ranked

RBC Capital

$52→$51

Buy

85.05%

Upside

Reiterated

04/06/26

Pharvaris price target lowered to $51 from $52 at RBC CapitalPharvaris price target lowered to $51 from $52 at RBC Capital

Jeff Jones

Oppenheimer

$50

Buy

81.42%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Prime Medicine, Inc. (NASDAQ: PRME) and Pharvaris (NASDAQ: PHVS)

Steven Seedhouse

Cantor Fitzgerald

$46

Buy

66.91%

Upside

Reiterated

02/22/26

Cantor Fitzgerald Sticks to Its Buy Rating for Pharvaris (PHVS)

Tazeen Ahmad

Bank of America Securities

$30

Hold

8.85%

Upside

Reiterated

01/27/26

Bank of America Securities Keeps Their Hold Rating on Pharvaris (PHVS)

Joseph Schwartz

Leerink Partners

$38

Buy

37.88%

Upside

Reiterated

01/13/26

Pharvaris (PHVS) Receives a Buy from Leerink Partners

Debanjana Chatterjee

JonesTrading

$48

Buy

74.17%

Upside

Reiterated

01/12/26

Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target

Debjit Chattopadhyay

Guggenheim

$32→$39

Buy

41.51%

Upside

Reiterated

12/03/25

Analysts Conflicted on These Healthcare Names: Masimo (NASDAQ: MASI), Bristol-Myers Squibb (NYSE: BMY) and Pharvaris (NASDAQ: PHVS)

Jonathan Wolleben

Citizens JMP

$55→$52

Buy

88.68%

Upside

Reiterated

08/13/25

Pharvaris price target lowered to $52 from $55 at Citizens JMPPharvaris price target lowered to $52 from $55 at Citizens JMP

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andy Chen

Wolfe Research

$42

Buy

52.39%

Upside

Initiated

04/08/26

Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and Pharvaris (NASDAQ: PHVS)

Maxwell Skor

Morgan Stanley

$41

Buy

48.77%

Upside

Reiterated

04/08/26

Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)

Patrick Trucchio

H.C. Wainwright

$60

Buy

117.71%

Upside

Reiterated

04/07/26

Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target

Laura Chico

Wedbush

$41→$42

Buy

52.39%

Upside

Reiterated

04/07/26

Pharvaris price target raised to $42 from $41 at WedbushPharvaris price target raised to $42 from $41 at Wedbush

Nevin Varghese

RBC Capital

Not Ranked

RBC Capital

$52→$51

Buy

85.05%

Upside

Reiterated

04/06/26

Pharvaris price target lowered to $51 from $52 at RBC CapitalPharvaris price target lowered to $51 from $52 at RBC Capital

Jeff Jones

Oppenheimer

$50

Buy

81.42%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Prime Medicine, Inc. (NASDAQ: PRME) and Pharvaris (NASDAQ: PHVS)

Steven Seedhouse

Cantor Fitzgerald

$46

Buy

66.91%

Upside

Reiterated

02/22/26

Cantor Fitzgerald Sticks to Its Buy Rating for Pharvaris (PHVS)

Tazeen Ahmad

Bank of America Securities

$30

Hold

8.85%

Upside

Reiterated

01/27/26

Bank of America Securities Keeps Their Hold Rating on Pharvaris (PHVS)

Joseph Schwartz

Leerink Partners

$38

Buy

37.88%

Upside

Reiterated

01/13/26

Pharvaris (PHVS) Receives a Buy from Leerink Partners

Debanjana Chatterjee

JonesTrading

$48

Buy

74.17%

Upside

Reiterated

01/12/26

Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target

Debjit Chattopadhyay

Guggenheim

$32→$39

Buy

41.51%

Upside

Reiterated

12/03/25

Analysts Conflicted on These Healthcare Names: Masimo (NASDAQ: MASI), Bristol-Myers Squibb (NYSE: BMY) and Pharvaris (NASDAQ: PHVS)

Jonathan Wolleben

Citizens JMP

$55→$52

Buy

88.68%

Upside

Reiterated

08/13/25

Pharvaris price target lowered to $52 from $55 at Citizens JMPPharvaris price target lowered to $52 from $55 at Citizens JMP

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharvaris

3 Months

xxx

Success Rate

15/26 ratings generated profit

Average Return

+2.83%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +2.83% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

19/27 ratings generated profit

Average Return

+60.55%

reiterated a buy rating 8 months ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 70.37% of your transactions generating a profit, with an average return of +60.55% per trade.

2 Years

xxx

Success Rate

25/27 ratings generated profit

Average Return

+61.16%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.59% of your transactions generating a profit, with an average return of +61.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PHVS Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PHVS has received 15 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. PHVS average Analyst price target in the past 3 months is 44.80.

Each month's total comprises the sum of three months' worth of ratings.

PHVS Financial Forecast

PHVS Earnings Forecast

The previous quarter’s earnings for PHVS were -$0.84.

No data currently available

PHVS Sales Forecast

The previous quarter’s earnings for PHVS were $0.00.

PHVS Stock Forecast FAQ

What is PHVS’s average 12-month price target, according to analysts?

Based on analyst ratings, Pharvaris’s 12-month average price target is 44.80.

What is PHVS’s upside potential, based on the analysts’ average price target?

Pharvaris has 62.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PHVS a Buy, Sell or Hold?

Pharvaris has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Pharvaris’s price target?

The average price target for Pharvaris is 44.80. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $30.00. The average price target represents 62.55% Increase from the current price of $27.56.

What do analysts say about Pharvaris?

Pharvaris’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of PHVS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Pharvaris (PHVS) Stock Forecast & Price Target

PHVS Analyst Ratings

PHVS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pharvaris

PHVS Analyst Recommendation Trends

PHVS Financial Forecast

PHVS Earnings Forecast

PHVS Sales Forecast

PHVS Stock Forecast FAQ

Detailed List of Analyst Forecasts